1. Introduction {#sec1-ijms-17-00962}
===============

The demand for recombinant proteins is growing globally because of their great application values in industry, diagnosis and therapy. The bioreactor systems that are used to produce recombinant proteins are becoming more important for producing large quantities of proteins, particularly those that have associated limitations due to cost or traditional source availability. Based on different types of organisms, several novel bioreactor systems were recently developed due to the advance in biotechniques. In general, a particular bioreactor system may be selected for a specific protein production based on costs as well as the integrity, purity and expression level of the protein.

Currently, recombinant proteins can be expressed in bacteria, yeasts, mammalian cell lines, transgenic animals and plants, and each of these bioreactor systems has specific advantages and limitations \[[@B1-ijms-17-00962],[@B2-ijms-17-00962],[@B3-ijms-17-00962]\]. As a source of natural products, bacteria and yeasts have long been employed in the production of small and simple recombination proteins at a relatively low cost \[[@B1-ijms-17-00962],[@B4-ijms-17-00962]\]. However, bacteria have no post-transcriptional and post-translational modifications, such as intron splicing, multimeric protein assembly, glycosylation and disulfide bond formation, and processes that are essential for generating functional eukaryotic proteins \[[@B5-ijms-17-00962],[@B6-ijms-17-00962]\]. Furthermore, heterologous proteins, expressed in intracellular with high levels, readily aggregate and form insoluble inclusion bodies that require expensive downstream processing \[[@B1-ijms-17-00962],[@B2-ijms-17-00962],[@B3-ijms-17-00962]\]. Despite the ability of yeasts to carry out post-translational modifications, the protein glycosylation pattern usually involves hyperglycosylation, which does not reflect what occurs in higher organisms \[[@B7-ijms-17-00962]\].

Mammalian cell lines are frequently used to produce proteins for therapeutic use; indeed, the USA has approved many different therapeutic and diagnostic proteins that are produced in mammalian cell lines \[[@B8-ijms-17-00962],[@B9-ijms-17-00962]\]. However, oxygen deficiency, the accumulation of waste product or sensitivity to stirring forces can result in instability of mammalian cells, making it difficult to culture these cells in large volumes \[[@B9-ijms-17-00962],[@B10-ijms-17-00962],[@B11-ijms-17-00962]\]. In addition, high levels of complex proteins can be obtained from the milk of transgenic animals \[[@B12-ijms-17-00962]\]. Regardless, the greatest disadvantage of mammalian bioreactor systems is contamination of agents and oncogenic sequences, which can cause diseases \[[@B13-ijms-17-00962]\].

Compared with the above-mentioned expression systems, transgenic plants provide numerous advantages, including the capacity to produce functional recombinant proteins at high levels in an inexpensive and safe manner. Furthermore, the scaling-up process for plants can more easily meet demands by utilizing existing agricultural processes ("molecular farming"), and the input is lower in contrast with other systems \[[@B14-ijms-17-00962]\]. As eukaryotes, plants are able to perform post-translational modifications; similar to animal cells, plant cells have pathways for protein synthesis and folding, and protein secretion and modification, which are required for pharmaceutical protein bioactivity \[[@B15-ijms-17-00962]\]. More importantly, plants cannot be infected by the major human pathogens, which may contaminate the systems of bacterial and mammalian \[[@B16-ijms-17-00962]\]. The expression levels of total soluble proteins (TSPs) obtained from transgenic plants range from 0.001% to 46.1% \[[@B17-ijms-17-00962],[@B18-ijms-17-00962]\], and the most of plants-produced human therapeutic proteins display structural, biochemical and functional properties that are very similar to proteins in humans and animal cell culture-produced proteins \[[@B19-ijms-17-00962],[@B20-ijms-17-00962]\].

Plants produce many types of proteins, including enzymes \[[@B21-ijms-17-00962]\], hormones \[[@B22-ijms-17-00962]\], functional vaccines \[[@B17-ijms-17-00962],[@B23-ijms-17-00962]\], antibodies \[[@B24-ijms-17-00962],[@B25-ijms-17-00962]\], and a variety of other therapeutic proteins \[[@B26-ijms-17-00962]\]. Examples of pharmaceutical proteins that are being expressed in plants include human growth hormone, human serum albumin, interferons, and erythropoietin \[[@B27-ijms-17-00962]\]. Several recent reviews describe the significant advances in this field \[[@B28-ijms-17-00962],[@B29-ijms-17-00962],[@B30-ijms-17-00962],[@B31-ijms-17-00962],[@B32-ijms-17-00962]\]. The first Food and Drug Administration (FDA)-approved plant-made biopharmaceutical (PMB) is glucocerebrosidase; this injectable product produced in carrot cells is used to treat a genetic/metabolic disorder \[[@B33-ijms-17-00962]\]. Another major advancement is the application of chloroplast-generated biopharmaceuticals for toxic antibody suppression \[[@B29-ijms-17-00962]\]. Chan and Daniell noted the challenges of plant cells-produced vaccine antigens toward clinical development, though these oral vaccines may be quite attractive for both human and veterinary purposes \[[@B31-ijms-17-00962],[@B34-ijms-17-00962]\].

Nonetheless, several disadvantages have hindered the use of plants as successful recombinant protein-producing system. Firstly, plants have different types of glycosylation patterns compared with animal cells, which may alter the function of the recombinant protein or even decrease immunogenicity; The second problem includes the controversial issues of regulations and safety, especially with regard to the risk of gene flow via transgenic pollen. Studies on gene flow between transgenic plants and native races have been reported, such as genes that encode *Bacillus thuringiensis* proteins in corn \[[@B35-ijms-17-00962]\] and herbicide resistance genes in canola \[[@B36-ijms-17-00962]\]; Third, much time is required from the transformation step to the acquisition of a purified protein. Moreover, the purification of proteins from plants is inconvenient because they cannot be secreted \[[@B37-ijms-17-00962]\].

Microalgae are a diverse photosynthetic group, consisting of eukaryotic organisms and prokaryotic cyanobacteria. Microalgae have unique advantages, including a high growth rate, ease of cultivation, low growth costs and metabolic pathways that are similar to those of higher plants, leading to the same post-transcriptional and post-translational modifications that occur in higher plants \[[@B38-ijms-17-00962],[@B39-ijms-17-00962]\]. Indeed, as photoautotrophic sunlight-driven cell factories, microalgae provide an efficient means of converting solar energy into biomass, producing fatty acids, lipids, vitamins, carbohydrates, antibiotics, antioxidants and proteins \[[@B40-ijms-17-00962],[@B41-ijms-17-00962]\].

Moreover, microalgae are valuable sources of novel biologically active products, and because their growth requires only inexpensive substrates, these cells can serve as economical and effective bioreactors for obtaining high added-value compounds for healthy food \[[@B42-ijms-17-00962],[@B43-ijms-17-00962],[@B44-ijms-17-00962]\]. Microalgae, such as *Spirulina maxima*, *Synechococcus* sp., *Scenedesmus obliquus*, *Porphyridium cruentum*, *Dunaliella salina*, *Chlorella vulgaris*, *Chlamydomonas reinhardtii*, and *Anabaena cylindrica* contain valuable nutrient compounds. However, microalgal cultivation began only several decades ago \[[@B45-ijms-17-00962],[@B46-ijms-17-00962]\].

In addition to naturally produced compounds, microalgae are also a promising platform for producing recombinant proteins and other valuable natural products, such as cosmetics, pharmaceuticals, biofuels and health supplements \[[@B47-ijms-17-00962],[@B48-ijms-17-00962],[@B49-ijms-17-00962],[@B50-ijms-17-00962]\], providing an attractive alternative to the current bioreactor systems. Compounds that are synthesized by microalgae include growth and blood-clotting factors, immune regulators, hormones, enzymes, monoclonal antibodies, viral vaccines, and other natural products, such as the anticancer agent Taxol. [Table 1](#ijms-17-00962-t001){ref-type="table"} roughly summarizes the advantages and disadvantages of bacteria, yeasts, cultured mammalian cells, animals, plants and microalgae for production purposes. This paper reviews the status of microalgae as bioreactors that produce pharmaceuticals.

2. Brief Introduction to Microalgae {#sec2-ijms-17-00962}
===================================

Algae include the microscopic (microalgae) and macroscopic forms (macroalgae) forms, with the latter largely consisting of seaweed. It has been estimated that there are one to ten million algae species, most of which are microalgae \[[@B53-ijms-17-00962]\]. Culturable microalgae can be classified into four categories: cyanobacteria, green algae, chrysophyte and red algae. Cyanobacteria, also known as blue-green algae, are distinguished from other bacteria because they perform oxygenic photosynthesis.

2.1. Growth Characteristics {#sec2dot1-ijms-17-00962}
---------------------------

An obvious and tangible diversity can be observed among microalgae. Their growth modes include phototrophy, photoheterotrophy, and heterotrophy, and each growth mode can be either obligate or facultative \[[@B54-ijms-17-00962]\].

Compared with plants traditionally used for production, microalgae have several advantages with respect to their growth characteristics. Microalgae do not require fertile soil; because microalgae can use nutrients quite efficiently, a medium that only contains essential nutrients can be used, thus avoiding water pollution due to unused fertilizers. Furthermore, some microalgae can grow in brackish water, saline water or seawater, which can help to conserve limited freshwater resources.

Microalgae photosynthesize under conditions of high light and low temperature. However, lack of essential nutrients, such as nitrogen, can result in starvation conditions, and nitrogen starvation leads to the cessation or slowing down of cell division, which then results in reduced utilization of photosynthetic products \[[@B55-ijms-17-00962],[@B56-ijms-17-00962],[@B57-ijms-17-00962]\]. Based on this, nitrogen starvation had been employed to manipulate the mass-cultivated microalgal metabolism to obtain lipids or carbohydrates-rich biomass \[[@B58-ijms-17-00962]\].

2.2. Nutrient Value {#sec2dot2-ijms-17-00962}
-------------------

Microalgae can improve the nutritive value of conventional food and animal feed and can effectively improve the health of humans and animals \[[@B59-ijms-17-00962]\]. As sources of protein, various microalgae are unconventional and contain a high protein content \[[@B60-ijms-17-00962]\]. The patterns of amino acids have advantages over that of other food proteins \[[@B61-ijms-17-00962]\]. Carbohydrates in microalgae exist in the forms of sugars, starch, glucose, and other polysaccharides, which are very easy to digest. Thus, whole dried microalgae can be used as supplements in food or feed with no limitations \[[@B62-ijms-17-00962]\].

The lipid content in some microalgae can account for 90% of the dry weight under certain conditions, with an average lipid content of 1% to 70% \[[@B63-ijms-17-00962]\]. As an essential component of lipids, fatty acids of the ω3 and ω6 families in microalgae are of special interest. Microalgae contain nearly all essential vitamins, such as nicotinate, biotin, folic acid and pantothenic acid \[[@B64-ijms-17-00962],[@B65-ijms-17-00962],[@B66-ijms-17-00962],[@B67-ijms-17-00962]\]. Moreover, there are large amounts of pigments, such as chloroiphyll, phycobiliproteins and carotenoids, in microalgae cells.

The production of nutritional supplements from microalgae has been a major research area in microalgal biotechnology for many years. Products generated from dried biomass or cell extracts of *Chlorella*, *Dunaliella* and *Spirulina* are marketed as nutraceuticals or health food and are sold for many hundreds of thousands of dollars \[[@B68-ijms-17-00962],[@B69-ijms-17-00962]\].

2.3. Genetic Research on Microalgae {#sec2dot3-ijms-17-00962}
-----------------------------------

Genetic research on microalgae has achieved great progress to date. The Calvin cycle was discovered through *Chlorella* research in 1948 \[[@B70-ijms-17-00962]\]. The genome sequences ofseveral microalgae including *Cyanobacteria* \[[@B71-ijms-17-00962],[@B72-ijms-17-00962]\], *Cyanidioschyzon merolae* \[[@B73-ijms-17-00962]\], *Thalassiosira pseudonana* \[[@B74-ijms-17-00962]\], and *C. reinhardtii* \[[@B75-ijms-17-00962]\] are publicly available. In addition, the genome sequence and genetic transformation of *Chlorella pyrenoidosa* \[[@B76-ijms-17-00962]\] and the oleaginous alga *Nannochloropsis gaditana* \[[@B77-ijms-17-00962]\], were reported.

*C. reinhardtii* is a model organism in microalgal genetics research, and much progress has been achieved using this organism in recent years. Fu *et al.* found that *N*^6^-methyldeoxyadenosine, a DNA modification, is an active transcriptional start sites in the genome of *Chlamydomonas* \[[@B78-ijms-17-00962]\]. Li *et al.* established an indexed, mapped *C. reinhardtii* mutant library that enables reverse genetic studies of biological processes in this species \[[@B79-ijms-17-00962]\]. Yang *et al.* described the disruption of *C. reinhardtii* ferredoxin-5 (FDX5) can lead to a dark growth deficiency and influence the membrane ultrastructure and membrane lipids \[[@B80-ijms-17-00962]\], and Dejtisakdi and Miller found that overexpression of *C. reinhardtii* fructose 1,6-bisphosphatase (CrFBPase) has a negative effect on growth \[[@B81-ijms-17-00962]\]. A mutation of starch deficiency in *Dunaliella tertiolecta* resulted in increased triacylglycerol content in the cells \[[@B82-ijms-17-00962]\], and the genomic basis for the Starch-to-Lipid Switch has been investigated in *Chlorella* \[[@B76-ijms-17-00962]\]. A new nuclear transformation method by microparticle bombardment was developed in *Phaeodactylum tricornutum* using PCR-amplified DNA fragments \[[@B83-ijms-17-00962]\]. In addition, Ferreira-Camargo *et al.* found that selenocystamine can improve accumulation of disulfide bonds-contained proteins in green algal chloroplasts \[[@B84-ijms-17-00962]\].

These studies helped to lay the foundation for research on microalgal applications, including genetic engineering.

3. Genetic Engineering and Production of Pharmaceuticals and Recombinant Proteins {#sec3-ijms-17-00962}
=================================================================================

3.1. Microalgal Transformation {#sec3dot1-ijms-17-00962}
------------------------------

As a platform for producing recombinant protein, the effective utilization of transgenic microalgae relies on stable transformation systems, including vector construction and transformation methods. Recombinant proteins are typically expressed by the genome of nucleus or chloroplast, which have important differences (see [Table 2](#ijms-17-00962-t002){ref-type="table"}). In the past 20 years, many species of microalgae were successfully transformed, most of which have been achieved via nuclear transformation \[[@B85-ijms-17-00962]\].

Typical methods for microalgal transformation are based on transient permeabilization of the cell membrane, which enables plasmid DNA to pass through the membrane and enter the cell. There are many methods for cell permeabilization. One method is to vortex the cells with the DNA, polyethylene glycol (PEG) and glass beads \[[@B86-ijms-17-00962]\]; this is simple, efficient, and suitable for transforming wild-type *Chlamydomonas* after enzyme-mediated cell wall degradation. Another method of *Chlamydomonas* transformation employs silicon carbide (SiC) whiskers, an approach that does not require removal of the cell wall \[[@B87-ijms-17-00962]\] and has been used to manipulate several microalgae, such as *Symbiodinium* and *Amphidinium* \[[@B88-ijms-17-00962]\]. However, SiC whiskers are harmful to human health and should not be the first choice. Electroporation was introduced for transferring genes into many types of cells and organisms, such as thin-walled cells, cell wall-reduced mutants, protoplasts, and naked cells, and is used to obtain stable *Chlamydomonas* transformants with high efficiency \[[@B89-ijms-17-00962],[@B90-ijms-17-00962]\]. In this method, the lipid bilayer is temporarily disrupted by an electronic pulse and DNA molecules are allowed to pass into the cell. Using this technique, the transformation of *C. reinhardtii*, *D. salina*, *C. vulgaris*, *Ostreococcus tauri*, and the red algae *Cyanidioschyzon merolae* has been successfully achieved. Microparticle bombardment is the preferred method of transformation for previously untransformed species of microalgae. Viruses, which infect brown algae and Chlorella-like algae, can also be used in microalgal transformation \[[@B91-ijms-17-00962],[@B92-ijms-17-00962]\], but this approach requires more investigation. In addition, the use of artificial transposons has expanded to the application of genetic transformation. Artificial mini-transposons contain elements of natural transposons that are essential for transposition, and a mini-transposon-transposase complex has been introduced into *Cyanobacterium spirulina* \[[@B93-ijms-17-00962]\]. Although eukaryotic microalgal transformation has not been reported to date using this method, the transposon approach may also be suitable for eukaryotic microalgae when no host factor is required. Particle bombardment is the most frequently used method for transformation of plant tissues and cells as well as prokaryotes; regarding microalgae, it has been successfully used in diatoms \[[@B94-ijms-17-00962],[@B95-ijms-17-00962],[@B96-ijms-17-00962],[@B97-ijms-17-00962]\]. Organelles can also been transformed using this method, such as chloroplasts and mitochondria \[[@B98-ijms-17-00962],[@B99-ijms-17-00962],[@B100-ijms-17-00962],[@B101-ijms-17-00962]\].

Chloroplast transformation has also been reported in the unicellular red algae *Porphyridium* sp. \[[@B98-ijms-17-00962]\]. The chloroplast transformation system of *Chlamydommonas* is the first and best studied in green algae \[[@B86-ijms-17-00962],[@B102-ijms-17-00962],[@B103-ijms-17-00962]\]. *Chlamydommonas* is an excellent model system for research because its genome has been sequenced \[[@B104-ijms-17-00962]\]. Many microalgal species have been stably transformed to date. A luciferase (Luc) and a homologous nitrate reductase gene have been transformed into *Chlorella* \[[@B105-ijms-17-00962]\]. Five heterololgous genes were transformed into the chloroplast of *D. tertiolecta*, and the recombinant enzymes were produced in a stable manner \[[@B106-ijms-17-00962]\]. Other economically valued chlorophytes, such as *Haematococcus pluvialis*, have been stably transformed through the development of a novel chloroplast expression vector \[[@B107-ijms-17-00962]\]. A food source in aquaculture, diatoms with silica-based cell walls, can also be used to produce therapeutic proteins, and six species, *Phaeodactylum tricornutum* \[[@B94-ijms-17-00962]\], *Cyclotella cryptica* \[[@B95-ijms-17-00962]\], *Navicula saprophila* (pennate diatoms) \[[@B95-ijms-17-00962]\], *Cylindrotheca fusiformis* \[[@B108-ijms-17-00962]\], *Thalassiosira weissflogii* \[[@B96-ijms-17-00962]\] and *Thalassiosira pseudonana* \[[@B109-ijms-17-00962]\], as well as *Chaetoceros* sp. (centric diatoms) \[[@B110-ijms-17-00962]\], have been transformed using the microparticle bombardment. Dinoflagellates, an important phytoplankton, are unicellular eukaryotic alveolar algae and some species have typical prokaryote characteristics and eukaryotic features. Among this group, *Amphidinium* and *Symbiodinium* have been successfully transformed \[[@B88-ijms-17-00962]\].

The application of selectable markers is essential for efficient transformation of microalgae. Several dominant and recessive markers have been investigated. Recessive markers have been chosen by functional complementation of the corresponding endogenous genes and mutants \[[@B111-ijms-17-00962]\]. Among these, nitrate reductase has been employed in *C. reinhardtii* \[[@B112-ijms-17-00962]\], *Volvox carteri* \[[@B113-ijms-17-00962]\], *Chlorella sorokiniana* \[[@B105-ijms-17-00962]\], and *Dunaliella viridis* \[[@B114-ijms-17-00962]\]. Dominant markers are the most widely used selectable markers that confer resistance to antibiotics or herbicides. In *Chlamydomonas*, *aadA* is used for resistance to spectinomycin and streptomycin \[[@B115-ijms-17-00962]\], *aphA*6 for resistance to kanamycin, *aph*7 for resistance to hygromycin B, the *aphVIII* for resistance to paromomycin \[[@B116-ijms-17-00962]\], *ble* for resistance to zeomycin and phleomycin \[[@B117-ijms-17-00962]\], the 16S ribosomal gene for resistance to spectinomycin; a mutated *als* gene also confers resistance to sulfonylurea herbicides \[[@B118-ijms-17-00962]\]. All of these markers provide effective, stable antibiotic resistance. In addition to *Chlamydomonas*, the *ble* gene can also be used in *Volvox carteri* \[[@B119-ijms-17-00962]\], *Phaeodactylum tricornutum* \[[@B94-ijms-17-00962],[@B96-ijms-17-00962]\], and *Cylindrotheca fusiformis* \[[@B108-ijms-17-00962]\]. Additionally, the *nptII* gene can be used in *Navicula saprophila*, *Cyclotella cryptica* \[[@B95-ijms-17-00962]\], in the dinoflagellates *Amphidinium* sp. and *Symbiodinium microadriaticum* \[[@B88-ijms-17-00962]\], in *Chlorella* \[[@B76-ijms-17-00962],[@B120-ijms-17-00962],[@B121-ijms-17-00962]\] and in the diatoms *Phaeodactylum tricornutum* \[[@B97-ijms-17-00962]\]. Different microalgal species exhibit diverse antibiotic sensitivities due to the presence of different marker genes \[[@B96-ijms-17-00962],[@B97-ijms-17-00962]\].

The promoter is an important aspect of successful microalgal transformation. For nuclear transformation in *P. tricornutum*, likely promoter choices are those of *fcpB* encoding chlorophyll a/c binding protein B of fucoxanthin \[[@B94-ijms-17-00962],[@B97-ijms-17-00962],[@B122-ijms-17-00962]\], and nitrate reductase, which is activated when nitrate is the nitrogen source in the medium \[[@B123-ijms-17-00962],[@B124-ijms-17-00962],[@B125-ijms-17-00962],[@B126-ijms-17-00962],[@B127-ijms-17-00962]\]. The CaMV35S promoter is also efficient in microalgae, such as *C. ellipsoidea* \[[@B128-ijms-17-00962],[@B129-ijms-17-00962],[@B130-ijms-17-00962]\], *C. vulgaris* \[[@B131-ijms-17-00962]\], *Haematococcus pluvialis* \[[@B132-ijms-17-00962]\], *D. salina* \[[@B133-ijms-17-00962],[@B134-ijms-17-00962],[@B135-ijms-17-00962]\] and *C. reinhardtii*. However, the expression level in *C. reinhardtii* is low. The RbcS2 promoter of *C. reinhardtii* has successfully been used in *C. ellipsoidea* for transient expression of the resistance gene or recombinant protein \[[@B128-ijms-17-00962],[@B131-ijms-17-00962]\]. The maize *Ubiquitin* (*Ubi*1) gene promoter can be used for stable expression of NP-1, an α-defensin encoded by a rabbit gene, in *C. ellipsoidea* \[[@B120-ijms-17-00962]\]. The tobacco mosaic virus (TMV) promoter enhances translation efficiency \[[@B130-ijms-17-00962]\], and in *D. salina* the ubiquitin-Ω promoter successfully drives expression of hepatitis B surface antigen \[[@B133-ijms-17-00962]\]. With regard to chloroplast transgenes, the *psbA*, *psbD* and *rbcL* promoters are typically used in *C. reinhardtii*. Recently, Seo *et al.* indicated that the EF2 promoter of *P. tricornutum* can be utilized for the expression of target gene in *P. tricornutum* and *C. reinhardtii* \[[@B136-ijms-17-00962]\].

Many species of microalgae had been successfully transformed; however, stable *Chlorella* transformants are lacking for a long time. *Chlorella* is an important genus in which a few species of microalgae can be used for industrial production, and genetic transformation of this group has important significance for employing *Chlorella* as a biological reactor. Although foreign gene transient expression has been successfully achieved in *Chlorella*, *C. sorokiniana* and *C. vulgaris*, none was able to produce target product \[[@B129-ijms-17-00962],[@B131-ijms-17-00962],[@B137-ijms-17-00962]\]. Flounder growth hormone (fGH) was produced in protoplasts of *C. ellipsoidea*, and it was accumulated to 400 mg/L estimated by ELISA \[[@B128-ijms-17-00962]\]. In our previous work, NP-1 was successfully expressed in *Chlorella* \[[@B130-ijms-17-00962]\], but the lines stably expressing NP-1 were not obtained because when the selection antibiotic G418 was removed, the NP-1-expressing cells were lost \[[@B138-ijms-17-00962]\]. Nonetheless, stable expression of foreign genes in transgenic *Chlorella* was achieved with technique improvement. For example, as stated above, a luciferase (Luc) gene and homologous nitrate reductase gene have been stably transformed into *Chlorella* \[[@B105-ijms-17-00962],[@B129-ijms-17-00962],[@B139-ijms-17-00962]\]. Defensin NP-1 can be produced in *C. ellipsoidea* \[[@B120-ijms-17-00962]\], and expression of GmDof4 in *C. ellipsoidea* can significantly increase the total lipid content. In *Chlorella pyrenoidosa*, overexpression of an *Arabidopsis thaliana* nicotinamide adenine dinucleotide (NAD(H)) kinase increased the lipid content of cells by 110.4% without effects on the growth rate \[[@B76-ijms-17-00962]\]. Recently, a new inducible expression system has also been developed for *Chlorella vulgaris* \[[@B140-ijms-17-00962]\].

Nuclear transgenic expression in microalgae is occasionally inefficient, possibly due to gene silencing \[[@B141-ijms-17-00962],[@B142-ijms-17-00962],[@B143-ijms-17-00962]\]. Furthermore, exogenous genes might not be expressed properly if the transgenic clones are not maintained under constant selection \[[@B144-ijms-17-00962]\]. With regard to the general feasibility of expressing foreign proteins in microalgae, it appears that despite the considerable body of knowledge accumulated, inducing high expression of transgenes is difficult, possibly due to epigenetic mechanisms \[[@B144-ijms-17-00962]\]. Other reasons for transient expression may include the following: (1) the heterologous genes might be not actually inserted into the genome, which can be detected by Southern hybridization, and Southern hybridization results were not provided in most of the papers reporting the transient expression of foreign genes in microalgae \[[@B129-ijms-17-00962],[@B145-ijms-17-00962],[@B146-ijms-17-00962]\]; (2) the selected transgenic colony contained non-transgenic cells, and without constant selection, the number of transgenic cells may have decreased or these cells may have disappeared. In our work on NP-1 expression in *C. ellipsoidea*, at least five rounds of continuous selection were performed to obtain stable transgenic lines \[[@B120-ijms-17-00962]\]. Therefore, to obtain stable transgenic *Chlorella*, a long period of continuous selection of individual clone is necessary.

3.2. Genetically Engineered Microalgae {#sec3dot2-ijms-17-00962}
--------------------------------------

Microalgal biotechnology has achieved important advances in recent years due to the development of new technologies \[[@B147-ijms-17-00962]\], and several examples in biotechnological applications of engineered microalgae have shown significant promise. In diatoms, Genetic engineering is an important approach of microalgae to produce particular lipids and bio-diesel \[[@B148-ijms-17-00962]\]. In *C. ellipsoidea*, overexpression of GmDof4, a soybean transcription factor, significantly increased the lipid content by 46.4% to 52.9% \[[@B121-ijms-17-00962]\]. In addition, researchers found that the expression of a foreign metallothionein gene can enhance the binding capacity to metals and the moth bean pyrroline-5-carboxylate synthetase (P5CS) gene expression can result in the accumulation of free proline in microalgae \[[@B149-ijms-17-00962],[@B150-ijms-17-00962]\].

Most of the advances in genetic engineering of microalgae have been realized in *C. reinhardtii* through the use of both nuclear and chloroplast transformation. *C. reinhardtii* is a good bioreactor for the production of many important recombinant proteins, including antibodies, protein therapeutics, vaccines, enzymes and additives, such as anti-CD22-gelonin single chain, viral protein 28 (VP28), erythropoietin, phytase (see [Table 3](#ijms-17-00962-t003){ref-type="table"}). A summary of information on the production of recombination proteins in *C. reinhardtii* and several other important microalgae is provided in [Table 3](#ijms-17-00962-t003){ref-type="table"}.

In addition to *C. reinhardtii*, several other microalgae have been studied and are considered more robust and more productive or are generally recognized and certified as safe, including species of *Chlorella*, *Scenedesmus* and *Dunaliella*. Although information about recombinant protein production in these species is lacking, in some cases, they can produce recombinant proteins at the same levels as *C. reinhardtii*. For example, five chloroplast industrial enzymes were produced in *D. tertiolecta*, accumulating in the same amounts as in *C. reinhardtii* \[[@B106-ijms-17-00962]\], and recombinant protein expression in *Scenedesmus dimorphus* has achieved the same results \[[@B179-ijms-17-00962]\]. Thus, other species of microalgae also have the ability to produce recombinant proteins \[[@B179-ijms-17-00962]\]. For instance, a monoclonal human IgG antibody against hepatitis B has been expressed in the diatom *P. tricornutum* \[[@B123-ijms-17-00962],[@B126-ijms-17-00962]\]. Because the codon usage of *P. tricornutum* is similar to that of humans \[[@B180-ijms-17-00962]\], this species could be beneficial for the production of biopharmaceuticals.

Additionally, successful *Porphytridium* spp., *Euglena gracilis* and *Haematococcus pluvialis* chloroplast transformation has also been reported \[[@B98-ijms-17-00962],[@B100-ijms-17-00962],[@B107-ijms-17-00962]\].

3.3. Production of Pharmaceuticals and Therapeutic Proteins {#sec3dot3-ijms-17-00962}
-----------------------------------------------------------

### 3.3.1. Subunit Vaccines {#sec3dot3dot1-ijms-17-00962}

As a platform for the production of subunit vaccines, transgenic microalgae have attracted considerable attention \[[@B181-ijms-17-00962]\]. Potential vaccine candidates have been produced against viruses and bacteria as well as malaria and other communicable diseases or have been investigated for non-viral diseases.

The E2 protein, which constitutes an antigen for vaccines against classical swine fever virus (CSFV), can be produced in *Chlamydomonas* chloroplast. The E2 protein can accumulate to 1.5%--2% of TSP \[[@B163-ijms-17-00962]\], and crude extracts of E2-transformed algae have been administered via subcutaneous injection and orally immunization in mice; the former resulted in a significant level of serum antibody against CSFV, whereas the later caused no immune response to E2.

Foot-and-mouth disease virus (FMDV) is an important virus that affects livestock. To produce a vaccine against FMDV in *C. reinhardtii*, the VP1 protein was fused with a potent mucosal adjuvant, cholera toxin B subunit (CTB). VP1-CTB can accumulate to 3% of TSP \[[@B154-ijms-17-00962]\] and exhibited binding affinity towards GM1-ganglioside, separately acting as an antigen for FMDV VP1 and CTB proteins, separately.

The gene that encodes the hepatitis B virus surface antigen (HBsAg) was successfully transformed into the green alga *D. salina* by electroporation, and stable nuclear transformants were obtained \[[@B133-ijms-17-00962]\]. Western blot analysis demonstrated HBsAg production, with levels of 1.6--3.1 ng/mg of total protein in different transformants with different insertion sites.

White Spot Syndrome Virus (WSSV) causes severe damage to shrimp farms worldwide. The main viral envelop protein of WSSV, Viral protein 28 (VP28), is a target for subunit vaccines \[[@B182-ijms-17-00962]\]. The gene encoding the VP28 protein was successfully transformed into the nuclear genome of *D. salina* and the chloroplast of *C. reinhardtii* \[[@B164-ijms-17-00962],[@B174-ijms-17-00962]\], with an output of 21% of total protein in the former case \[[@B164-ijms-17-00962]\], and approximately 3 ng/mg of total protein in the latter \[[@B174-ijms-17-00962]\]. Under the challenge of WSSV, the survival rate of Ds-VP28-vaccinated crayfish was 41%, much higher than the control group, which had a mortality rate of 100%. This indicated that oral administration of VP28-transformed algae can protect crayfish against viral pathogens.

*Staphylococcus aureus* is a bacterium that can cause skin infections, respiratory diseases and food poisoning. The fused protein of D2 fibronectin-binding domain of *S. aureus* and the CTB mucosal adjuvant was stably expressed in the chloroplast of *Chlamydomonas* \[[@B166-ijms-17-00962]\]. The fused D2-CTB protein was accumulated to 0.7% of TSP, and oral administration to mice caused both systemic IgG and mucosal IgA responses. Oral vaccination of mice with D2-CTB protected against a lethal dose of *S. aureus*, which is the first demonstration of the efficacy of an oral vaccine produced in algae.

Vaccines have been developed to prevent or treat cancers. The FDA has approved Gardasil and Cervarix as cancer vaccines to protect against human papillomavirus (HPV) types 16 and 18, which is the arch-criminal of about 70% of cervical cancer cases. A transgene encoding the E7 oncoprotein of HPV-16 was transformed to *C. reinhardtii* and accumulated to 0.12% of TSP \[[@B155-ijms-17-00962]\]. The experiment of subcutaneous injections showed that protection with high levels were achieved after the E7 protein expressed in a tumour cell line, which indicated that green microalgae can be used as a viable platform to produce cancer vaccines.

Glutamic acid decarboxylase-65 (GAD65) is a major autoantigen for human type 1 diabetes, which is an autoimmune disease resulting from the destruction of insulin-producing beta cells in the pancreas. By immunizing non-obese diabetic (NOD) mice, studies on type 1 diabetes found that GAD65 can prevent or delay diabetes onset \[[@B183-ijms-17-00962]\]. The expression level of human GAD65 in the chloroplasts of *C. reinhardtii* can reach 0.25% to 0.3% of TSP \[[@B165-ijms-17-00962]\], and the algal-derived hGAD65 reacts with diabetic sera and has the ability to induce the proliferation of spleen lymphocytes from NOD mice.

Many other vaccines have been expressed in microalgae, such as *C. reinhardtii*-produced malaria vaccines \[[@B167-ijms-17-00962],[@B169-ijms-17-00962]\] that fuse the algal starch matrix protein called granule-bound starch synthase (GBSS) with apical major antigen (AMA1) and major surface protein (MSP1), two clinically relevant malaria antigens, separately. Experiments showed a significant reduction in parasitemia and an increased life span, and the immune sera from GBSS-MSP1 immunized mice resulted in strongly protection against malarial infection \[[@B167-ijms-17-00962]\].

One strategy for malaria eradication includes the combination of transmission blocking vaccines (TBVs) for preventing the disease spread with drug-based therapies. As potential TBVs, Pfs48/45, Pfs25, and Pfs28, which are difficult to produce in traditional expression systems, were transformed into *Chlamydomonas* \[[@B168-ijms-17-00962],[@B169-ijms-17-00962]\]. The transmission of *Plasmodium* oocytes can be completely blocked by antibodies against algal-expressed Pfs25. Mice fed freeze-dried Pfs25-CTB produced in algae displayed a mucosal IgA response to Pfs25 and CTB, and elicited serum IgG antibodies against CTB. Because no IgG antibodies of Pfs25 were elicited, malaria transmission couldn't be blocked. However, this study does support that the transgenic algae are promising to produce oral vaccines against mucosal infections \[[@B170-ijms-17-00962],[@B179-ijms-17-00962]\].

Immunotherapy is a promising alternative to conventional drug therapy for hypertension. A chimeric protein, angiotensin II fused with a nucleocapsid antigen of hepatitis B virus (HBcAg) was produced in *C. reinhardtii*. The expression levels of this fused protein reached 0.05% of TSP in several transgenic lines; but the immunogenic properties of antigen derived from the HBcAgII algae still need to be assessed \[[@B176-ijms-17-00962]\].

By modifying gene codons, HIV antigen P24 was expressed in *Chlamydomonas*, with the level of recombinant protein accounting for up to 0.25% of the total cellular protein \[[@B177-ijms-17-00962]\]. In addition, a new recombinant protein that is a chimaera fused the CTB mucosal adjuvant with the p210 epitope of ApoB100 (CTB:p210) was expressed in the chloroplasts of *C. reinhardtii* as an approach to create an oral vaccine against atherosclerosis. The production of this fusion protein can reach 60 μg/g of fresh algae weight. The immunogenic activity was tested by orally administration in BALB/c mice, and elicited anti-p210 serum antibodies, which can last for at least 80 days \[[@B178-ijms-17-00962]\].

### 3.3.2. Antibodies, Immunotoxins, Antimicrobial Agents and Others {#sec3dot3dot2-ijms-17-00962}

Monoclonal antibody is an effective therapy for the treatment of various human diseases. The first mammalian protein produced in the chloroplast of microalgae was a monoclonal antibody protecting human against glycoprotein D of herpes simplex virus (HSV). This large single-chain (lsc) antibody, which is a fusion protein of the entire IgA heavy chain and the light chain variable region via a flexible linker, was expressed in *C. reinhardtii* chloroplast \[[@B151-ijms-17-00962]\].

Immunotoxins, consisting of a toxin molecule and an antibody domain, can bind to target cells and inhibit its proliferation, thus can be used to kill cancer cells in anti-cancer therapies. Using a single-chain antibody fragment targeting a B-cell surface epitope CD22, fused with exotoxin A enzymatic domain from *Pseudomonas aeruginosa*, Tran *et al.* found that both the monovalent and divalent immunotoxins can be produced and assembled in chloroplast of microalgae \[[@B153-ijms-17-00962]\]. Furthermore, both immunotoxin molecules can significantly inhibit tumour growth in animal experiments, improving mouse survival rate in the assay of tumour-challenge \[[@B153-ijms-17-00962]\]. Similar results were observed when gelonin, a different eukaryotic toxin from *Gelonium multiflorum*, was fused to monovalent and divalent anti-CD22 single-chain antibodies \[[@B152-ijms-17-00962]\].

Defensins, a kind of small cationic peptides, can be used as promising alternative to antibiotics. For example, mature rabbit neutrophil peptide 1 (NP-1), an α-defensin with a broad anti-microbial activity that can defend against gram-negative or positive bacteria, certain viruses, and pathogenic fungi, has been successfully transformed into *C. ellipsoidea* \[[@B120-ijms-17-00962]\].

Flounder growth hormone (fGH) can be expressed in *C. ellipsoidea* and accumulate to approximately 400 μg per liter. Flounder fry fed transgenic *Chlorella* increased by 25% in length and width within 30 days \[[@B128-ijms-17-00962]\].

Several types of enzymes have been successfully produced in microalgae. A gene from *E. coli* encoding a bioactive phytase enzyme (AppA) was expressed in *C. reinhardtii*, and AppA algae can significantly reduce the phytate content and increase the content of inorganic phosphate in chick manure when used as a direct food additive \[[@B171-ijms-17-00962]\]. Moreover, bioactive xylanase and two α-galactosidases have been expressed in the chloroplasts of *C. reinhardtii* and *D. tertiolecta* \[[@B106-ijms-17-00962]\]. In particular, *C. reinhardtii* nuclear genome transformation resulted in more than 100-fold the xylanase activity when xylanase was fused to a secretion signal, self-processing viral peptide (2A), and the selection marker gene *ble* \[[@B172-ijms-17-00962]\].

We summarized the potential pharmaceuticals and recombinant proteins that were produced from microalgae and tested in animal experiments in [Table 4](#ijms-17-00962-t004){ref-type="table"}.

4. Discussions and Conclusions {#sec4-ijms-17-00962}
==============================

Microalgae are important natural resources that contain valuable proteins, oils, fatty acids, polysaccharides and other bioactive proteins that are currently commercially available. Moreover, as a new type of bioreactor, microalgae can produce recombinant pharmaceutical proteins, such as vaccines and antibodies. In this review, we outlined significant potential avenues for microalgal production of pharmaceuticals.

Subunit vaccines are mainly produced and delivered from expensive injection administration of purified protein. In the microalgal production of pharmaceuticals, the use of microalgae to produce oral vaccines could be highly promising. It had been proved that several vaccine antigens can accumulate and correctly fold in microalgae, and some fusion proteins with increased antigenicity can be effectively delivered orally. These give a potential alternative way to produce subunit vaccines by making oral tablet of microalgae inexpensively with systemic and mucosa immune reactivities \[[@B181-ijms-17-00962]\]. A better acknowledgement of the immune responses of adjuvants and orally proteins will promote the development of oral vaccines significantly \[[@B184-ijms-17-00962]\].

According to advances in microalgal research, it appears that *C. reinhardtii* is the most promising microalgae for producing pharmaceuticals. In addition to *C. reinhardtii*, other microalgae have been preliminarily considered as bioreactors for pharmaceutical production, but some species, such as *Chlorella spp*. and *Phaeodactylum tricornutum*, may be more promising due to recent significant achievements in research of their genomes \[[@B83-ijms-17-00962],[@B146-ijms-17-00962],[@B185-ijms-17-00962],[@B186-ijms-17-00962]\]. Indeed, these microalgae have advantages compared with *C. reinhardtii*, such as ease of cultivation, edibility (*Chlorella*), rapid growth, and ease of industrialized production. Nevertheless, *Chlorella* is small in size and possesses a resilient cell wall; thus, utilization of *Chlorella* for recombinant protein expression is hampered by a lack of genetic tools. Although several reports have shown stable expression of transgenes in *Chlorella* \[[@B76-ijms-17-00962],[@B120-ijms-17-00962],[@B129-ijms-17-00962],[@B139-ijms-17-00962]\], achieving stable transformation in *Chlorella* is still difficult compared to many other microalgae due to unstable nuclear integration, position effects, inefficient selection of transgenic cells, inefficient transcription of heterologous genes, inaccurate RNA processing, and the bias of codon usage. In addition, transformed strains are easily lost during passaging once the selective pressure has been removed \[[@B187-ijms-17-00962]\]. Therefore, the development of sophisticated genetic tools such as a powerful expression box would be helpful for nuclear and chloroplast transformations in *Chlorella* genetic engineering.

With regard to plants, after decades of work, the first biopharmaceutical-taliglucerase alfa, which was produced in cultured carrot cells, was approved by the FDA of the United States for treatment with Gaucher's Disease in 2012 \[[@B188-ijms-17-00962],[@B189-ijms-17-00962],[@B190-ijms-17-00962],[@B191-ijms-17-00962],[@B192-ijms-17-00962]\]. Several plant-based oral vaccines have been assessed in clinical trials to determine their safety and immunogenicity \[[@B193-ijms-17-00962],[@B194-ijms-17-00962],[@B195-ijms-17-00962],[@B196-ijms-17-00962]\]. Despite the many advantages for pharmaceutical production and the significant advances, especially for *C. reinhardtii*, the microalgal approach for bioreactors is still in its infancy. To date, no pharmaceuticals produced from microalgae have obtained approval for commercial production or are under clinical trial, and only a few subunit vaccines/recombinant proteins were tested in animal experiments (see [Table 4](#ijms-17-00962-t004){ref-type="table"}). Therefore, extensive work remains to be performed before microalgae can be used for large-scale production of pharmaceuticals for commercial use.

The following aspects should be given more attention in future work: (1) transgenic microalgal safety evaluations according to the regulations of different countries; (2) production standards for recombinant pharmaceutical proteins under GMP conditions, including transgenic algal culture at a large scale, algal cell processing, protein purification, structural and function characterizations and product quality control; (3) preclinical trials to verify product safety and efficiency; and (4) clinical trials.

"The application of algal systems to edible vaccines is increasingly gaining interest", comments from Christoph Griesbeck. "Aside from biopharmaceuticals, an additional application of algae for pharmaceutical products could involve novel metabolites improved by metabolic engineering" \[[@B197-ijms-17-00962]\]. With the development of new techniques for molecular manipulation and metabolic engineering, advances in microalgal approaches will inevitably be achieved, and the significant potential of these organisms as routine expression systems for the manufacture of pharmaceuticals will be realized in the near future.
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###### 

Rough comparison among different expression platforms to produce pharmaceuticals (modified from \[[@B51-ijms-17-00962],[@B52-ijms-17-00962]\]).

  Expression Systems         Bacteria     Yeasts      Cultured Mammalian Cells   Animals     Plants              Microalgae
  -------------------------- ------------ ----------- -------------------------- ----------- ------------------- -------------------
  Protein folding accuracy   Low          Medium      High                       High        High                High
  Glycosylation              None         Incorrect   Correct                    Correct     Minor Differences   Minor Differences
  Product quality            Low          Medium      High                       High        High                High
  Protein yield              Medium       High        High                       High        High                High
  Production scale           Limited      Limited     Limited                    Limited     Worldwide           High
  Production time            Short        Medium      Long                       Long        Long                Short
  Scale-up cost              High         High        High                       High        Medium              Low
  Overall cost               Medium       Medium      High                       High        Low                 Low
  Contamination risk         Endotoxins   Low         High                       High        Low                 Low
  Safety                     Low          Unknown     High                       High        High                High
  Storage cost               Moderate     Moderate    Expensive                  Expensive   Inexpensive         Low
  Distribution               Medium       Medium      Difficult                  Difficult   Easy                Very easy
  Reproduction               Easy         Easy        Difficult                  Medium      Easy                Very easy

ijms-17-00962-t002_Table 2

###### 

Differences between the genome engineering of the nucleus and chloroplast.

  Genome Engineering          Nucleus                                                        Chloroplast
  --------------------------- -------------------------------------------------------------- ---------------------------------
  Gene expression machinery   Eukaryotic                                                     Prokaryotic
  Protein localization        Cytoplasm, nucleus, chloroplast, ER, mitochondria, secretion   Chloroplast
  Modifications               Phosphorylation, glycosylation, disulfide bond                 Phosphorylation, disulfide bond
  Accumulation levels         Low                                                            High
  Transformation methods      Electroporation, biolistic, glass beads, silicon whiskers      Biolistic
  Integration mode            Non-homologous end joining                                     Homologous recombination

ijms-17-00962-t003_Table 3

###### 

Summary information of recombinant proteins manufactured in several important microalgae.

  Microalgae            Transformation Method   Expressed Genes                      Promoters                     Selective Marker Genes                                                     Products                                          Expression Location (Chloroplast/Nucleus)   Product Content or Activity                  References
  --------------------- ----------------------- ------------------------------------ ----------------------------- -------------------------------------------------------------------------- ------------------------------------------------- ------------------------------------------- -------------------------------------------- ---------------------------
  *Amphidinium* sp.     SiC whiskers            *Gus*                                CaMV 35S                      *nptII* gene (neomycin resistance), *hpt* gene (hygromycin resistance)     β-glucoronidase                                   Nucleus                                     --                                           \[[@B88-ijms-17-00962]\]
  *C. reinhardtii*      Particle bombardment    *lsc*                                atpA or rbcL                  a 16S ribosomal gene (spectinomycin resistance)                            Anti-HSV glycoprotein D Isc                       Chloroplast                                 \>1% of TSP                                  \[[@B151-ijms-17-00962]\]
  *C. reinhardtii*      Particle bombardment    *gelonin*                            psbA                          *aphA*6 (kanamycin resistance)                                             Anti-CD22-gelonin sc                              Chloroplast                                 0.1%--0.2% of TSP                            \[[@B152-ijms-17-00962]\]
  *C. reinhardtii*      Particle bombardment    *Exotoxin A*                         psbA                          *aphA*6                                                                    Anti-CD22-ETA sc                                  Chloroplast                                 0.2%--0.3% of TSP                            \[[@B153-ijms-17-00962]\]
  *C. reinhardtii*      Particle bombardment    *VP1*, *CTB*                         atpA                          *aadA* (spectinomycin resistance)                                          VP1-CTB                                           Chloroplast                                 3% of TSP                                    \[[@B154-ijms-17-00962]\]
  *C. reinhardtii*      Glass beads method      *E7GGG*                              psbD                          *aadA*                                                                     E7GGG                                             Chloroplast                                 0.12% of TSP                                 \[[@B155-ijms-17-00962]\]
  *C. reinhardtii*      Particle bombardment    *VEGF*                               psbA                          *aphA*6                                                                    VEGF                                              Chloroplast                                 2% of TSP                                    \[[@B156-ijms-17-00962]\]
  *C. reinhardtii*      Particle bombardment    *HMGB1*                              psbA                          *aphA*6                                                                    HMGB1                                             Chloroplast                                 2.5% of TSP                                  \[[@B156-ijms-17-00962]\]
  *C. reinhardtii*      Particle bombardment    *14FN3*                              psbA                          *aphA*6                                                                    14FN3                                             Chloroplast                                 3% of TSP                                    \[[@B156-ijms-17-00962]\]
  *C. reinhardtii*      Particle bombardment    *metallothionein*-*2*                psbA                          *aadA*                                                                     Metallothionein-2                                 Chloroplast                                 --                                           \[[@B157-ijms-17-00962]\]
  *C. reinhardtii*      Particle bombardment    *Strail*                             atpA                          *aadA*                                                                     TRAIL                                             Chloroplast                                 0.43%--0.67% of TSP                          \[[@B158-ijms-17-00962]\]
  *C. reinhardtii*      Particle bombardment    *apcA* and *apcB*                    psbA                          *aadA*                                                                     Allophycocyanin                                   Chloroplast                                 2%--3% of TSP                                \[[@B159-ijms-17-00962]\]
  *C. reinhardtii*      --                      IgG1 *lc, hc*                        psbA                          *aadA*                                                                     Anti-PA 83 anthrax IgG1                           Chloroplast                                 100 μg/g of dry algal biomass                \[[@B160-ijms-17-00962]\]
  *C. reinhardtii*      Glass beads method      *crEpo*                              HSP70A/RBCS2                  *ARG*7                                                                     Erythropoietin                                    Nucleus                                     100 μg /L                                    \[[@B161-ijms-17-00962]\]
  *C. ellipsoidea*      Electroporation         *mNP-1*                              Ubi1                          *Npt*II and *NR* genes                                                     mNP-1                                             Nucleus                                     11.42 mg/L                                   \[[@B120-ijms-17-00962]\]
  *C. reinhardtii*      Particle Bombardment    *m-saa*                              psbA                          --                                                                         M-SAA (bovine mammary-associated serum amyloid)   Chloroplast                                 5% of TSP                                    \[[@B162-ijms-17-00962]\]
  *C. reinhardtii*      Particle bombardment    *E2*                                 atpA                          *aadA*                                                                     Swine fever virus (CSFV) structural protein       Chloroplast                                 1.5%--2% of TSP                              \[[@B163-ijms-17-00962]\]
  *C. reinhardtii*      Particle bombardment    *VP28*                               psbA                          *aadA*                                                                     VP28                                              Chloroplast                                 21% of TCP (about 42% of TSP)                \[[@B164-ijms-17-00962]\]
  *C. reinhardtii*      Particle bombardment    *hGAD65*                             rbcL                          a 16S ribosomal gene                                                       hGAD65                                            Chloroplast                                 0.3% of TSP                                  \[[@B165-ijms-17-00962]\]
  *C. reinhardtii*      Particle bombardment    *CTB*, *D2*                          rbcL                          aadA                                                                       CTB-D2                                            Chloroplast                                 0.7% of TSP                                  \[[@B166-ijms-17-00962]\]
  *C. reinhardtii*      Glass beads method      *PfMSP*~1-19~                        HSP70A/RbcS2                  *AphVIII* gene (paromomycin resistance)                                    GBSS-PfMSP~1--19~                                 Nucleus                                     --                                           \[[@B167-ijms-17-00962]\]
  *C. reinhardtii*      Glass beads method      *PbAMA*~1-C~                         HSP70A/RbcS2                  *AphVIII* gene                                                             GBSS-PbAMA~1-C~                                   Nucleus                                     --                                           \[[@B167-ijms-17-00962]\]
  *C. reinhardtii*      Particle bombardment    *Pfs25*                              psbA                          *kanR* (a kanamycin resistance cassette)                                   Pfs25                                             Chloroplast                                 --                                           \[[@B168-ijms-17-00962]\]
  *C. reinhardtii*      Particle bombardment    *Pfs28*                              psbA                          *kanR*                                                                     Pfs28                                             Chloroplast                                 --                                           \[[@B168-ijms-17-00962]\]
  *C. reinhardtii*      Particle bombardment    *c.r.pfs48/45*                       psbA/psbD                     --                                                                         c.r.Pfs48/45                                      Chloroplast                                 --                                           \[[@B169-ijms-17-00962]\]
  *C. reinhardtii*      Particle bombardment    *Cr.ctxB-pfs25*                      psbA                          *kanR*                                                                     Cr.CtxB-Pfs25                                     Chloroplast                                 --                                           \[[@B170-ijms-17-00962]\]
  *C. reinhardtii*      Particle bombardment    *appA*                               atpA                          --                                                                         AppA phytase                                      Chloroplast                                 --                                           \[[@B171-ijms-17-00962]\]
  *C. reinhardtii*      Electroporation         *xyn1*                               PAR4 (hsp70A and the rbcs2)   *aph*7 gene (hygromycin B resistance), *sh-ble* gene (zeocin resistance)   β-1,4-endoxylanase                                Nucleus                                     --                                           \[[@B172-ijms-17-00962]\]
  *C. reinhardtii*      LiAc/PEG                *fGH*                                CaMV 35S                      *Sh ble* gene (phleomycin resistance)                                      Flounder growth hormone                           Nucleus                                     420 μg of fGH protein per liter of culture   \[[@B128-ijms-17-00962]\]
  *C. reinhardtii*      Glass beads method      *human Sep15*                        Hsp70-RBCS2                   *ble* gene (zeocin resistance)                                             Human Sep15 protein                               Nucleus                                     --                                           \[[@B173-ijms-17-00962]\]
  *D. salina*           Electroporation         *HBsAg*                              ubiquitin-Ω                   *CAT* gene (chloramphenicol resistance)                                    HBsAg                                             Nucleus                                     1.6--3.1 ng/mg                               \[[@B133-ijms-17-00962]\]
  *D. salina*           Glass beads method      *VP28*                               Ubi1-Ω                        --                                                                         VP28                                              Nucleus                                     3 ng/mg                                      \[[@B174-ijms-17-00962]\]
  *D.tertiolecta*       Particle bombardment    *xylanase/α-galactosidase/phytase*   psbD                          Erythromycin esterase (erythromycin resistance)                            Xylanase/α-galactosidase/phytase                  Chloroplast                                 --                                           \[[@B106-ijms-17-00962]\]
  *L. amoebiformis*     Particle bombardment    *RbcS*                               LarbcS1 promoter              --                                                                         Rubisco small subunit (RbcS) protein              Nucleus                                     --                                           \[[@B175-ijms-17-00962]\]
  *Porphyridium* sp.    Particle bombardment    *AHAS* (*W492S*)                     Endogenous AHAS promoter      *AHAS*                                                                     acetohydroxyacid synthase                         Chloroplast                                 --                                           \[[@B98-ijms-17-00962]\]
  *P.tricornutum*       Particle bombardment    IgG *LC*, *HC*                       Nitrate reductase promoter    --                                                                         Monoclonal human IgG antibody against HBsAg       Chloroplast                                 8.7% of TSP, 21 mg/g of dry algal biomass    \[[@B123-ijms-17-00962]\]
  *S.microadriaticum*   SiC whiskers            *Gus*                                CaMV 35S                      *nptII* gene, *hpt* gene                                                   β-glucoronidase                                   Nucleus                                     --                                           \[[@B88-ijms-17-00962]\]
  *C. reinhardtii*      Agrobacterium           *HBcAgII*                            CaMV 35S                      *NptII* (kanamycin resistance)                                             HBcAg-GS-AgII-GS-HBcAg                            Chloroplast                                 0.02%--0.05% of TSP                          \[[@B176-ijms-17-00962]\]
  *C. reinhardtii*      Glass beads method      *P24*                                *PSAD* promoter               *aphVIII* gene (paromomycin resistance)                                    subunit of HIV-1 viral particles                  Nucleus                                     0.25% of the total cellular protein          \[[@B177-ijms-17-00962]\]
  *C. reinhardtii*      Particle bombardment    *CTB:p210*                           *atpA*                        *aadA* gene (spectinomycin resistance)                                     the p210 epitope from ApoB100                     Chloroplast                                 up to 60 μg/g of fresh weight biomass        \[[@B178-ijms-17-00962]\]

*C. reinhardtii* represents *Chlamydomonas reinhardtii*; *C. ellipsoidea* represents *Chlorella ellipsoidea*; *D. salina* represents *Dunaliella salina*; *S. microadriaticum* represents *Symbiodinium microadriaticum*; *L. amoebiformis* represents *Lotharella amoebiformis*; *P. tricornutum* represents *Phaeodactylum tricornutum*; TSP represents total soluble proteins.
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###### 

Preclinical trials of recombinant proteins expressed in microalgae.

  Recombinant Proteins               Preclinical Trials                                                                                                                                                                                                                                                                  Activity Analysis                    References
  ---------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------ ---------------------------
  Anti-CD22-ETA sc                   Compared with mice treated with the antibody deficient immune toxin, mice treated with immunotoxin produced by algae can significantly inhibit the propagation of tumor, suggesting immunotoxins expressed in algae significantly affect tumor progression in animal experiments.   --                                   \[[@B153-ijms-17-00962]\]
  VP1-CTB                            The CTB-VP1, fusion protein expressed in *C. reinhardtii* chloroplast, exhibited significant binding affinity to GM1-ganglioside.                                                                                                                                                   Southern blot, Western blot, ELISA   \[[@B154-ijms-17-00962]\]
  E7GGG                              E7GGG expressed in *Chlamydomonas* elicited tumor protection in 60% of mice. Mice vaccinated with the purified E7GGG-FLAG protein were 100% tumor-free after 9 weeks.                                                                                                               Western blot, ELISA                  \[[@B155-ijms-17-00962]\]
  E2                                 Responsing against CSFV, E2 can induce significant serum antibody by subcutaneous immunization, but oral immunization resulted in no detectable serum response.                                                                                                                     Southern blot, Western blot          \[[@B163-ijms-17-00962]\]
  hGAD65                             Algal-derived hGAD65 had higher binding capacity to diabetic serum samples and can stimulate proliferation of splenic T cells from NOD mice *in vitro*, demonstrating its antigenic and immunogenic characteristics.                                                                Western blot                         \[[@B165-ijms-17-00962]\]
  CTB-D2                             Oral vaccination of CTB-D2 to mice induced responses of specific systemic and mucosal immune against *S. aureus*.                                                                                                                                                                   --                                   \[[@B166-ijms-17-00962]\]
  GBSS-pfMSP~1-19~ GBSS-pfAMA~1-C~   The starch antigens accumulated in the chloroplast can protect against lethal *P. berghei* infection in mice.                                                                                                                                                                       Western blot                         \[[@B167-ijms-17-00962]\]
  Cr.CtxB-Pfs25                      Oral vaccination of Cr.CtxB-Pfs25-producing algae to mice elicited IgG and IgA antibodies to CTB, and IgG antibodies to Pfs25.                                                                                                                                                      ELISA                                \[[@B170-ijms-17-00962]\]
  AppA phytase                       AppA-producing algae can significantly reduce the phytate content and increase the content of inorganic phosphate content in chick manure.                                                                                                                                          --                                   \[[@B171-ijms-17-00962]\]
  fGH                                Flounder fry fed with transgenic *Chlorella* increased by 25% within 30 days in length and width.                                                                                                                                                                                   Southern blot, immunoblot            \[[@B128-ijms-17-00962]\]
  VP28                               Survival rates of crayfish vaccinated by Ds-VP28 were significantly higher (59% mortality) than the positive control groups and Ds empty control (100% mortality).                                                                                                                  Western blot, ELISA                  \[[@B174-ijms-17-00962]\]
  p210 epitope from ApoB100          The immunogenic activity was tested by orally administration in BALB/c mice, and elicited anti-p210 serum antibodies, which can last for at least 80 days.                                                                                                                          Western blot, ELISA                  \[[@B178-ijms-17-00962]\]
